Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428766 | 1.00 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL4428770 | 1.00 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL21029706 | 0.82 | GABRR1 (0.31) | GABRR1PLGPLATLMNA | |
| SCHEMBL13631051 | 0.82 | GABRR1 (0.31) | GABRR1PLGPLATLMNA | |
| SCHEMBL3581962 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL5260434 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL3953001 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL3953002 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL3581424 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL6567963 | 0.80 | GABRR1 (0.48) | GABRR1PLGPLATLMNAABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106316889-B | Preparation method of edoxaban intermediate | 上海阳帆医药科技有限公司 | 2020-07-10 | — | — | CN | claimed |
| CN-106316889-B | Preparation method of edoxaban intermediate | 上海阳帆医药科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-106316889-B | Preparation method of edoxaban intermediate | 上海阳帆医药科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20090105491-A1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1925611-A1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105491-A1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | TFPI, F2, SERPINC1 | GABRR1 2669/4885PLG 29/4885PLAT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.